National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

edatrexate
A polyglutamatable folate antagonist analogue of methotrexate with antineoplastic activity. Edatrexate inhibits dihydrofolate reductase, thereby increasing cellular levels of polyglutamates, inhibiting thymidylate synthase and glycinamide ribonucleotide formyl transferase, impairing synthesis of purine nucleotides and amino acids, and resulting in tumor cell death. Edatrexate may overcome tumor resistance to methotrexate, which loses its activity after it is polyglutamated. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Abbreviations:10-EdAM
EDAM
Code name:CGP-30694
Chemical structure names:
  • 10-ethyl-10-deaza-aminopterin
  • N-[4-[1-[(2,4-diamino-6-pteridinyl)-methyl]propyl]benzoyl]-L-glutamic acid



Previous:E7080, E7820, echinomycin, Ecotrin, eculizumab
Next:Edecrin, edotecarin, edrecolomab, EF5, efalizumab

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov